What started out as shoulder pain turned into a living nightmare for a Melbourne girl and her family after doctors discovered a large mass in the eight-year-old’s chest, which turned out to be a rare ...
Phothera, the leading manufacturer of FDA-cleared light therapy devices for chronic skin conditions including vitiligo, psoriasis, atopic dermatitis, and cutaneous T-cell lymphoma (CTCL), today ...
Consider the case of patient WB, a 79-year-old male with recurrent diffuse large B cell lymphoma. He was referred for ...
A fasting-derived ketone metabolite reshapes CAR T cell metabolism and gene activity, boosting immune cell expansion, energy ...
Detailed price information for Citius Pharmaceuticals Inc (CTXR-Q) from The Globe and Mail including charting and trades.
Who are the Grey's Anatomy cast who died in real life? Find out their identities, dig into their profiles, their character, and impact they left in the industry.
So welcome to our second IR went in 2026, focusing this time on the Phase III ALLEGORY results for Gazyva in SLE, which just got presented last Friday at SLEuro. Today's call is scheduled for 60 ...
Mansfield and Ashfield Chad on MSN
Sutton man takes on the 2026 London Marathon challenge for Children with Cancer UK
Lee Roberts from Sutton in Ashfield is running the TCS London Marathon in aid of Children with Cancer UK, the leading ...
Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically ...
Clinicians must consider patient comorbidities and therapy safety when selecting immunotherapy for cSCC, says Todd ...
News-Medical.Net on MSN
Biomimetic platform enhances CAR T therapy for relapsed and refractory leukemia
Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically engineering a chimeric antigen receptor on the surface of the patient's T ...
News-Medical.Net on MSN
Microbial ecosystems influence success of cancer checkpoint immunotherapy
Immune checkpoint inhibitors targeting PD-1 and PD-L1 have revolutionized cancer therapy, delivering long-term survival benefits in several malignancies. However, nearly half of patients show limited ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results